CliffBio
small molecule

ICLUSIG

PONATINIB HYDROCHLORIDE

Loss of exclusivityDecember 2033latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameICLUSIG
Active ingredientPONATINIB HYDROCHLORIDE
StrengthEQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2020
Marketing statusRX

Listed patents

PatentExpiresType
9493470December 2033substance, product
11384086December 2033substance, product
11192897December 2033substance
11192895December 2033use U-1948
8114874January 2027substance, product
9029533December 2026use U-1699

Regulatory exclusivity

CodeExpires
ODE-472March 2031
I-934March 2027

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.